Genentech logo

Positive late-stage results for Genentech’s ocrelizumab in different forms of MS

October 8, 2015
Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab

Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …

obesity

Innovative pipeline can transform obesity treatment, says GBI Research

October 8, 2015
Research and Development obesity

While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …

troponin_blood_test

Simple blood test can accurately predict imminent heart attacks

October 8, 2015
Research and Development NHS, heart attack

A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …

Gilenya

Novartis looks to new measure of Gilenya outcomes

October 8, 2015
Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis

Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015
Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …

Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015
Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …

Nobel Prize

Infectious diseases dominate Nobel Prize awards for medicine

October 8, 2015
Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness

Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …

ms_symptoms

Multiple Sclerosis treatment will be a $20bn market by 2024

October 7, 2015
Research and Development multiple sclerosis

The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …

ms_early_intervention

Experts call for greater urgency in MS treatment

October 7, 2015
Research and Development multiple sclerosis

A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …

ferring_president

PROFILE: Ambitious Ferring wants to be global fertility leader

October 7, 2015
Manufacturing and Production, Research and Development Ferring, peptides

The stunning view of the Alps across Lake Geneva from Ferring’s corporate headquarters in Saint-Prex seems appropriate for a company …

amerisourcebergen

AmerisourceBergen acquires sterile compounder PharMEDium for $2.5bn

October 7, 2015
Research and Development, Sales and Marketing AmerisourceBergen, mergers and acquisitions

AmerisourceBergen will now source compounded drugs for its hospital clients by manufacturing them itself after spending more than $2.5 billion …

akabia_logo

Akebia passes vadadustat for anaemia phase III study with FDA & EMA

October 7, 2015
Research and Development Akabia, FDA, anaemia

Akebia Therapeutics has announced the successful completion of the End-of-Phase II Meeting process with the FDA and the Scientific Advice …

joachim_hoeltz

Rondo AG appoints Joachim Hoeltz as chief exec

October 7, 2015
Manufacturing and Production, Research and Development, Sales and Marketing

Joachim Hoeltz has been appointed chief executive at pharmaceutical packaging company Rondo AG within the Business Area Medipak Systems. He …

merckincweb

NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment

October 7, 2015
Research and Development Merck, NHS, NICE, keytruda, skin cancer

The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …

aubagio

Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial

October 7, 2015
Research and Development Genzyme, MS, Sanofi

Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …

aristada

FDA approves Alkermes schizophrenia treatment

October 6, 2015
Research and Development Alkermes, Aristada, FDA, schizophrenia

The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …

flu_vaccien_smaller

Flu jab reduces risk of stroke for two months

October 6, 2015
Research and Development flu vaccine, stroke

The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a …

oral_insulin

Moving forward in diabetes

October 6, 2015
Research and Development Novo Nordiak, diabetes

As many as 387 million people worldwide are living with diabetes, and it is predicted that by 2035 more than …

diabetes_uk_logo

Novo Nordisk and Diabetes UK extend ‘Clinical Champions’ initiative

October 6, 2015
Medical Communications Novo Nordisk, diabetes

Diabetes UK and Novo Nordisk have announced the appointment of 20 Diabetes UK ‘Clinical Champions’, who will be supported and …

david-luther

David Luther joins MISSION Therapeutics

October 6, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing

Cambridge, UK-based MISSION Therapeutics has announced the appointment of David Luther as chief financial officer.Luther brings more than 25 years’ …

The Gateway to Local Adoption Series

Latest content